Cromos Pharma

In the latest edition of Cromos Pharma's Newsletter, we highlight key developments shaping clinical research and drug development:

– ASCO 2026:Five major trends that are influencing the future of oncology research.
– Influenza: The FDA approves the first single-dose generic treatment for the flu.
– Clinical Trial Design: Why the growing "endpoint bubble" is making studies more complex.
– Fentanyl: A first-in-human vaccine enters clinical testing.

Read the full Newsletter: https://cromospharma.com/clinical-research-focus-54th-edition/

Greetings from BIO 2026!

Cromos Pharma’s US Business Development Director, Nicole Brenna, is spending the week connecting with sponsors, partners, and biotech innovators from around the world.

BIO is always a great reminder that our industry is built on relationships as much as science. Throughout the week, Nicole has been participating in partnering meetings, networking events, and conversations with colleagues and industry peers, making the most of every opportunity to reconnect, exchange ideas, and build new connections.

Nicole also joined the traditional BIO 5K Run, a long-standing conference tradition that brings attendees together outside the meeting rooms and provides another opportunity to connect with fellow industry professionals.

Looking forward to more conversations and collaborations throughout the week!

As clinical trial protocols become more complex, sponsors face an important challenge: ensuring that every measurement serves a purpose.

In this article, Cromos Pharma CEO Vlad Bogin, MD, FACP, explores the growing issue of endpoint expansion and why endpoint discipline may be critical to better study outcomes and decision-making.

Read the article: https://cromospharma.com/the-endpoint-bubble-why-clinical-trials-are-drowning-in-measurements-that-don-t-matter/